Deutsche Bank AG Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Deutsche Bank AG raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 62.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,361 shares of the company's stock after buying an additional 9,750 shares during the period. Deutsche Bank AG owned about 0.09% of Krystal Biotech worth $3,973,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC raised its stake in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. raised its stake in Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after buying an additional 6,600 shares during the last quarter. Hood River Capital Management LLC raised its stake in Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Citigroup decreased their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 6th. Chardan Capital reissued a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Guggenheim cut their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $211.13.

Krystal Biotech Trading Down 0.2%

Krystal Biotech stock traded down $0.24 during mid-day trading on Friday, hitting $125.05. The stock had a trading volume of 298,645 shares, compared to its average volume of 308,069. The firm has a market capitalization of $3.61 billion, a P/E ratio of 41.82 and a beta of 0.79. The firm's 50 day moving average is $161.34 and its 200 day moving average is $166.79. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).